Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Brian Skorney maintains an Outperform rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and raises the price target from $34 to $39.
June 17, 2024 | 4:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird analyst Brian Skorney maintains an Outperform rating on Mirum Pharmaceuticals and raises the price target from $34 to $39.
The analyst's decision to maintain an Outperform rating and raise the price target suggests a positive outlook on Mirum Pharmaceuticals' future performance. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100